Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.34 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | SI | P14410 | 2/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081827 | 0.86 | NR1I3 (0.34) | MAPTNR1I3ALOX5GAAMGAM | |
| SCHEMBL18081782 | 0.85 | MAPT (0.41) | MAPTSMPD3NR1I3SLC9A1GAA | |
| SCHEMBL16631706 | 0.82 | NR1I3 (0.36) | MAPTNR1I3ALOX5GAAMGAM | |
| SCHEMBL18080506 | 0.81 | MAPT (0.35) | MAPTSMPD3NR1I3 | |
| SCHEMBL16631924 | 0.81 | NR1I3 (0.31) | NR1I3ALOX5 | |
| SCHEMBL16631918 | 0.79 | SLC9A1 (0.35) | MAPTSMPD3ALOX5SLC9A1GAA | |
| SCHEMBL16631556 | 0.76 | NR1I3 (0.40) | MAPTNR1I3ALOX5GAAMGAM | |
| SCHEMBL18081968 | 0.75 | NR1I3 (0.33) | MAPTNR1I3 | |
| SCHEMBL18081969 | 0.72 | L3MBTL1 (0.33) | MAPTOPRK1KMT2A | |
| SCHEMBL16631940 | 0.72 | OPRK1 (0.41) | MAPTOPRK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | MAPT 3290/4885SMPD3 1349/4885NR1I3 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.